News AMD shadows NVIDIA with a move into AI drug discovery Chipmaker AMD has taken a 20% stake in Absci, a specialist in the use of artificial intelligence in for biologic drug discovery.
News AstraZeneca links with Absci on AI for biologics discovery AstraZeneca has agreed a deal worth up to $247 million with US generative artificial intelligence (GenAI) company Absci that will focus on the discovery of a new antibody-
News Changing Faces: pharma supplier, DTx, and non-profit hires f... A number of pharma-adjacent tech firms and non-profits announced personnel news in the month of November. We’ve rounded up some highlights below.
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
